159,477 Shares in Clover Health Investments, Corp. $CLOV Purchased by Landscape Capital Management L.L.C.

Key Points

• Landscape Capital Management L.L.C. has made a new investment in Clover Health Investments, purchasing 159,477 shares valued at approximately $573,000.
• CEO Conrad Wai sold 118,600 shares of Clover stock at an average price of $3.29, representing a 7.35% decrease in their position.
• Analyst ratings for Clover Health show an average rating of "Moderate Buy" with a consensus price target of $4.37.

Landscape Capital Management L.L.C. bought a new stake in Clover Health Investments, Corp. (NASDAQ:CLOV - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 159,477 shares of the company's stock, valued at approximately $573,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CLOV. Rhumbline Advisers raised its position in Clover Health Investments by 80.5% in the 1st quarter. Rhumbline Advisers now owns 7,085 shares of the company's stock worth $25,000 after purchasing an additional 3,160 shares during the period. Perigon Wealth Management LLC purchased a new stake in shares of Clover Health Investments in the 1st quarter worth approximately $36,000. Triumph Capital Management acquired a new stake in Clover Health Investments during the 4th quarter worth about $45,000. Deutsche Bank AG boosted its holdings in Clover Health Investments by 149.4% during the first quarter. Deutsche Bank AG now owns 16,307 shares of the company's stock worth $59,000 after buying an additional 9,768 shares in the last quarter. Finally, FORA Capital LLC purchased a new stake in shares of Clover Health Investments during the 1st quarter valued at approximately $60,000. Hedge funds and other institutional investors own 19.77% of the company's stock.

Insider Activity at Clover Health Investments

In other Clover Health Investments news, CEO Conrad Wai sold 91,197 shares of the firm's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $3.32, for a total value of $302,774.04. Following the sale, the chief executive officer directly owned 1,403,701 shares in the company, valued at approximately $4,660,287.32. This trade represents a 6.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Anna U. Loengard acquired 26,500 shares of the stock in a transaction dated Wednesday, August 13th. The shares were bought at an average cost of $2.59 per share, for a total transaction of $68,635.00. Following the acquisition, the director owned 29,610 shares in the company, valued at $76,689.90. The trade was a 852.09% increase in their position. The disclosure for this purchase can be found here. 24.07% of the stock is currently owned by company insiders.

Clover Health Investments Stock Up 2.0%

Shares of Clover Health Investments stock traded up $0.06 during trading hours on Friday, reaching $2.75. 1,433,754 shares of the stock traded hands, compared to its average volume of 7,148,272. The firm has a market capitalization of $1.41 billion, a price-to-earnings ratio of -34.31 and a beta of 1.96. Clover Health Investments, Corp. has a one year low of $2.12 and a one year high of $4.87. The company has a 50 day moving average price of $2.77 and a 200 day moving average price of $3.24.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. UBS Group cut their price objective on shares of Clover Health Investments from $4.50 to $3.00 and set a "neutral" rating on the stock in a report on Wednesday, August 6th. Canaccord Genuity Group decreased their target price on Clover Health Investments from $4.50 to $4.10 and set a "buy" rating for the company in a research note on Thursday, August 7th. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $4.37.

About Clover Health Investments

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.